Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial
Duvelisib联合罗米地辛治疗复发/难治性T细胞淋巴瘤:一项1b/2a期试验
期刊:Nature Medicine
影响因子:58.7
doi:10.1038/s41591-024-03076-6
Steven M Horwitz ,Ajit J Nirmal ,Jahan Rahman # ,Ran Xu # ,Esther Drill ,Natasha Galasso ,Nivetha Ganesan ,Theresa Davey ,Helen Hancock ,Leslie Perez ,Catherine Maccaro ,Alexandra Bahgat ,Evan Marzouk ,Elizabeth Cathcart ,Alison Moskowitz ,Ariela Noy ,Anita Kumar ,Eric Jacobsen ,David C Fisher ,Neha Mehta-Shah ,Youn H Kim ,Michael Khodadoust ,Nikita Kotlov ,Anastasia Nikitina ,Olga Kudryashova ,Valeria Zubareva ,Ksenia Zornikova ,Nara Shin ,Maria Sorokina ,Sandrine Degryse ,Ekaterina Postovalova ,Aleksander Bagaev ,Kinga Hosszu ,Devin McAvoy ,Jaap J Boelens ,Wenchao Wu ,Zoe Ciantra ,Jackson W Appelt ,Christopher Trevisani ,Sam Amaka ,David M Weinstock ,Santosha A Vardhana